Share Price and Basic Stock Data
Last Updated: December 27, 2025, 8:59 pm
| PEG Ratio | -6.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hikal Ltd operates within the pharmaceuticals industry, with a current market capitalization of ₹2,885 Cr and a share price of ₹234. In terms of revenue, the company reported sales of ₹2,023 Cr for the year ending March 2023, reflecting a growth trajectory from ₹1,943 Cr in March 2022. However, preliminary data for the fiscal year 2025 indicates a decline in sales to ₹1,860 Cr, suggesting potential challenges in maintaining growth momentum. Quarterly sales figures from June 2022 to June 2025 show fluctuations, with the highest quarterly sales recorded at ₹559 Cr in September 2022, and the most recent quarterly sales of ₹453 Cr in September 2024. This inconsistency may indicate market volatility or operational challenges affecting revenue generation. The trailing twelve months (TTM) sales stand at ₹1,699 Cr, which further underscores the need for strategic initiatives to stabilize revenue growth.
Profitability and Efficiency Metrics
In terms of profitability, Hikal Ltd reported a net profit of ₹78 Cr for the year ending March 2023, a significant drop from ₹160 Cr in March 2022. The profit margins also reflected this trend, with a net profit margin of 3.87% for the TTM, down from 8.26% the previous year. The company’s operating profit margin (OPM) stood at 13% for March 2023, a decrease from 18% in March 2022. Notably, the interest coverage ratio (ICR) was reported at 4.43x, indicating a healthy ability to meet interest obligations, but the return on equity (ROE) was relatively low at 7.38%. Efficiency metrics show a cash conversion cycle (CCC) of 116 days, which is on the higher side compared to industry standards, indicating potential inefficiencies in inventory management or receivables collection. The fluctuation in quarterly operating profit, peaking at ₹123 Cr in March 2025, highlights the volatility in operational performance.
Balance Sheet Strength and Financial Ratios
Hikal Ltd’s balance sheet presents a mixed picture, with total borrowings reported at ₹683 Cr against reserves of ₹1,170 Cr, indicating a debt-to-equity ratio of approximately 0.60x. This level of leverage is moderate, allowing for growth opportunities without excessive financial risk. However, the company reported fixed assets of ₹1,364 Cr and total assets of ₹2,529 Cr for March 2025, suggesting a substantial investment in physical infrastructure. The company’s return on capital employed (ROCE) stood at 10% for March 2025, which is lower than the typical sector range, indicating that capital utilization may not be optimal. The current ratio of 1.26x shows a stable liquidity position, while the quick ratio of 0.83x indicates some risk in meeting short-term obligations. Overall, while Hikal has a robust asset base, its profitability and returns on capital employed warrant attention.
Shareholding Pattern and Investor Confidence
Hikal Ltd’s shareholding pattern indicates a strong promoter holding of 68.85%, which suggests a significant level of control and commitment from the management. However, the foreign institutional investor (FII) stake has seen a decline from 6.14% in December 2023 to 4.23% in September 2025, signaling potential concerns among international investors about the company’s growth prospects. Domestic institutional investors (DIIs) increased their stake to 5.15%, reflecting a moderate level of confidence in the company’s performance. The total number of shareholders stood at 73,404 as of September 2025, suggesting a stable investor base. The consistent promoter holding provides a degree of stability, but the decline in FII interest may raise questions regarding market perception and investor confidence in Hikal’s future performance.
Outlook, Risks, and Final Insight
Looking ahead, Hikal Ltd faces a mixed outlook characterized by both potential growth opportunities and notable risks. On the one hand, the company’s established market presence and strong promoter backing position it well for future endeavors. However, risks such as declining sales figures, fluctuating profit margins, and a high cash conversion cycle could hamper growth. The need for operational efficiency improvements and strategic initiatives to stabilize revenue and enhance profitability is evident. The fluctuating interest from institutional investors may also impact market confidence. In summary, while Hikal Ltd possesses strengths in its asset base and management commitment, addressing operational challenges and improving profitability metrics will be crucial for sustaining investor interest and achieving long-term growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,102.29 Cr | 1,150.17 | 52.68 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 379 | 559 | 540 | 545 | 388 | 435 | 448 | 514 | 407 | 453 | 448 | 552 | 380 |
| Expenses | 356 | 489 | 466 | 457 | 338 | 377 | 383 | 420 | 349 | 378 | 376 | 429 | 355 |
| Operating Profit | 23 | 70 | 75 | 88 | 50 | 58 | 65 | 94 | 58 | 75 | 72 | 123 | 25 |
| OPM % | 6% | 12% | 14% | 16% | 13% | 13% | 14% | 18% | 14% | 17% | 16% | 22% | 7% |
| Other Income | 3 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| Interest | 11 | 11 | 13 | 13 | 14 | 13 | 14 | 15 | 20 | 19 | 19 | 18 | 17 |
| Depreciation | 26 | 27 | 28 | 27 | 28 | 29 | 29 | 32 | 32 | 32 | 33 | 38 | 39 |
| Profit before tax | -12 | 33 | 36 | 49 | 10 | 17 | 22 | 47 | 7 | 25 | 24 | 68 | -30 |
| Tax % | -25% | 24% | 26% | 26% | 29% | 25% | 25% | 28% | 26% | 26% | 28% | 26% | -26% |
| Net Profit | -9 | 25 | 26 | 36 | 7 | 13 | 16 | 34 | 5 | 18 | 17 | 50 | -22 |
| EPS in Rs | -0.72 | 2.01 | 2.14 | 2.92 | 0.56 | 1.02 | 1.31 | 2.75 | 0.41 | 1.48 | 1.39 | 4.07 | -1.82 |
Last Updated: August 20, 2025, 9:40 am
Below is a detailed analysis of the quarterly data for Hikal Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 380.00 Cr.. The value appears to be declining and may need further review. It has decreased from 552.00 Cr. (Mar 2025) to 380.00 Cr., marking a decrease of 172.00 Cr..
- For Expenses, as of Jun 2025, the value is 355.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 429.00 Cr. (Mar 2025) to 355.00 Cr., marking a decrease of 74.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2025) to 25.00 Cr., marking a decrease of 98.00 Cr..
- For OPM %, as of Jun 2025, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 7.00%, marking a decrease of 15.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to -30.00 Cr., marking a decrease of 98.00 Cr..
- For Tax %, as of Jun 2025, the value is -26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -26.00%, marking a decrease of 52.00%.
- For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 72.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.82. The value appears to be declining and may need further review. It has decreased from 4.07 (Mar 2025) to -1.82, marking a decrease of 5.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,699 |
| Expenses | 642 | 689 | 745 | 813 | 1,054 | 1,291 | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,471 |
| Operating Profit | 187 | 182 | 181 | 201 | 242 | 298 | 273 | 323 | 341 | 258 | 267 | 328 | 228 |
| OPM % | 23% | 21% | 20% | 20% | 19% | 19% | 18% | 19% | 18% | 13% | 15% | 18% | 13% |
| Other Income | 34 | 2 | 2 | -3 | 4 | 2 | -12 | 5 | 5 | 5 | 2 | 5 | 7 |
| Interest | 68 | 60 | 62 | 48 | 49 | 58 | 52 | 36 | 31 | 48 | 56 | 75 | 69 |
| Depreciation | 55 | 64 | 67 | 69 | 86 | 93 | 82 | 85 | 96 | 109 | 118 | 134 | 152 |
| Profit before tax | 98 | 60 | 53 | 80 | 112 | 149 | 127 | 206 | 219 | 105 | 96 | 124 | 15 |
| Tax % | 35% | 32% | 23% | 16% | 31% | 31% | 33% | 36% | 27% | 26% | 27% | 27% | |
| Net Profit | 64 | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 160 | 78 | 70 | 91 | 10 |
| EPS in Rs | 5.17 | 3.28 | 3.34 | 5.49 | 6.26 | 8.36 | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.36 | 0.81 |
| Dividend Payout % | 12% | 20% | 20% | 15% | 13% | 14% | 18% | 19% | 12% | 19% | 21% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -37.50% | 2.50% | 65.85% | 13.24% | 33.77% | -18.45% | 58.33% | 20.30% | -51.25% | -10.26% | 30.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.00% | 63.35% | -52.62% | 20.53% | -52.21% | 76.78% | -38.03% | -71.55% | 40.99% | 40.26% |
Hikal Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -1% |
| 3 Years: | -17% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 10% |
| 3 Years: | -8% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 6:05 am
Balance Sheet
Last Updated: December 10, 2025, 2:47 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 488 | 516 | 547 | 589 | 653 | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 | 1,170 |
| Borrowings | 546 | 547 | 505 | 598 | 635 | 661 | 646 | 610 | 675 | 748 | 818 | 765 | 683 |
| Other Liabilities | 219 | 212 | 206 | 177 | 237 | 268 | 306 | 370 | 470 | 504 | 482 | 502 | 472 |
| Total Liabilities | 1,270 | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,349 |
| Fixed Assets | 644 | 639 | 623 | 668 | 634 | 713 | 735 | 713 | 879 | 948 | 1,071 | 1,364 | 1,340 |
| CWIP | 61 | 62 | 66 | 63 | 118 | 79 | 161 | 254 | 295 | 412 | 414 | 121 | 134 |
| Investments | 3 | 3 | 3 | 4 | 3 | 1 | 1 | 1 | 11 | 5 | 5 | 10 | 10 |
| Other Assets | 562 | 588 | 583 | 645 | 788 | 893 | 871 | 946 | 1,028 | 1,020 | 997 | 1,034 | 865 |
| Total Assets | 1,270 | 1,292 | 1,275 | 1,379 | 1,542 | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,349 |
Below is a detailed analysis of the balance sheet data for Hikal Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,170.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,238.00 Cr. (Mar 2025) to 1,170.00 Cr., marking a decrease of 68.00 Cr..
- For Borrowings, as of Sep 2025, the value is 683.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 765.00 Cr. (Mar 2025) to 683.00 Cr., marking a decrease of 82.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 472.00 Cr.. The value appears to be improving (decreasing). It has decreased from 502.00 Cr. (Mar 2025) to 472.00 Cr., marking a decrease of 30.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,349.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,529.00 Cr. (Mar 2025) to 2,349.00 Cr., marking a decrease of 180.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,340.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,364.00 Cr. (Mar 2025) to 1,340.00 Cr., marking a decrease of 24.00 Cr..
- For CWIP, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 121.00 Cr. (Mar 2025) to 134.00 Cr., marking an increase of 13.00 Cr..
- For Investments, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Other Assets, as of Sep 2025, the value is 865.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,034.00 Cr. (Mar 2025) to 865.00 Cr., marking a decrease of 169.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,349.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,529.00 Cr. (Mar 2025) to 2,349.00 Cr., marking a decrease of 180.00 Cr..
Notably, the Reserves (1,170.00 Cr.) exceed the Borrowings (683.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -359.00 | -365.00 | -324.00 | -397.00 | -393.00 | -363.00 | -373.00 | -287.00 | -334.00 | -490.00 | -551.00 | -437.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 39 | 54 | 44 | 92 | 81 | 80 | 82 | 103 | 82 | 80 | 113 | 103 |
| Inventory Days | 302 | 268 | 229 | 189 | 158 | 156 | 147 | 107 | 121 | 104 | 134 | 146 |
| Days Payable | 127 | 117 | 101 | 93 | 86 | 68 | 95 | 92 | 91 | 103 | 123 | 133 |
| Cash Conversion Cycle | 214 | 205 | 173 | 188 | 153 | 168 | 135 | 118 | 112 | 81 | 124 | 116 |
| Working Capital Days | 0 | -13 | 29 | 43 | 29 | 45 | 28 | 39 | 26 | 39 | 39 | 37 |
| ROCE % | 16% | 11% | 11% | 12% | 13% | 15% | 14% | 16% | 15% | 8% | 8% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Small Cap Fund | 3,300,000 | 0.64 | 73.56 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 2,652,267 | 0.92 | 59.12 | 2,274,918 | 2025-12-14 02:40:07 | 16.59% |
| Tata India Pharma & HealthCare Fund | 393,821 | 0.66 | 8.78 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 7.36 | 5.64 | 6.36 | 13.02 | 10.80 |
| Diluted EPS (Rs.) | 7.36 | 5.64 | 6.36 | 13.02 | 10.80 |
| Cash EPS (Rs.) | 18.23 | 15.18 | 15.20 | 20.78 | 17.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 102.21 | 96.32 | 91.93 | 86.62 | 75.70 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 102.21 | 96.32 | 91.93 | 86.62 | 75.70 |
| Revenue From Operations / Share (Rs.) | 150.59 | 144.74 | 164.07 | 157.56 | 139.53 |
| PBDIT / Share (Rs.) | 27.00 | 21.86 | 21.29 | 28.02 | 26.59 |
| PBIT / Share (Rs.) | 16.11 | 12.32 | 12.45 | 20.26 | 19.68 |
| PBT / Share (Rs.) | 10.02 | 7.75 | 8.55 | 17.73 | 16.74 |
| Net Profit / Share (Rs.) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 |
| NP After MI And SOA / Share (Rs.) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 |
| PBDIT Margin (%) | 17.92 | 15.10 | 12.97 | 17.78 | 19.05 |
| PBIT Margin (%) | 10.70 | 8.51 | 7.58 | 12.85 | 14.10 |
| PBT Margin (%) | 6.65 | 5.35 | 5.20 | 11.25 | 11.99 |
| Net Profit Margin (%) | 4.88 | 3.90 | 3.87 | 8.26 | 7.73 |
| NP After MI And SOA Margin (%) | 4.88 | 3.90 | 3.87 | 8.26 | 7.73 |
| Return on Networth / Equity (%) | 7.19 | 5.86 | 6.91 | 15.02 | 14.26 |
| Return on Capital Employeed (%) | 11.44 | 8.77 | 8.90 | 17.29 | 19.31 |
| Return On Assets (%) | 3.59 | 2.79 | 3.28 | 7.25 | 6.95 |
| Long Term Debt / Equity (X) | 0.29 | 0.35 | 0.43 | 0.26 | 0.28 |
| Total Debt / Equity (X) | 0.60 | 0.68 | 0.65 | 0.63 | 0.55 |
| Asset Turnover Ratio (%) | 0.74 | 0.73 | 0.87 | 0.94 | 0.93 |
| Current Ratio (X) | 1.26 | 1.28 | 1.42 | 1.25 | 1.34 |
| Quick Ratio (X) | 0.83 | 0.87 | 0.94 | 0.82 | 0.93 |
| Inventory Turnover Ratio (X) | 5.83 | 2.60 | 3.47 | 3.47 | 3.13 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 21.25 | 15.73 | 16.90 | 11.11 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 7.90 | 6.57 | 10.58 | 6.77 |
| Earning Retention Ratio (%) | 0.00 | 78.75 | 84.27 | 83.10 | 88.89 |
| Cash Earning Retention Ratio (%) | 0.00 | 92.10 | 93.43 | 89.42 | 93.23 |
| Interest Coverage Ratio (X) | 4.43 | 4.78 | 5.46 | 11.07 | 9.06 |
| Interest Coverage Ratio (Post Tax) (X) | 2.21 | 2.23 | 2.63 | 6.14 | 4.68 |
| Enterprise Value (Cr.) | 5685.34 | 4058.84 | 4164.23 | 5587.56 | 2246.86 |
| EV / Net Operating Revenue (X) | 3.06 | 2.27 | 2.06 | 2.88 | 1.31 |
| EV / EBITDA (X) | 17.05 | 15.06 | 15.87 | 16.17 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 2.66 | 1.83 | 1.72 | 2.55 | 1.03 |
| Retention Ratios (%) | 0.00 | 78.74 | 84.26 | 83.09 | 88.88 |
| Price / BV (X) | 3.91 | 2.75 | 3.07 | 4.65 | 1.90 |
| Price / Net Operating Revenue (X) | 2.66 | 1.83 | 1.72 | 2.55 | 1.03 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.03 | 0.07 |
After reviewing the key financial ratios for Hikal Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.23. This value is within the healthy range. It has increased from 15.18 (Mar 24) to 18.23, marking an increase of 3.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.59. It has increased from 144.74 (Mar 24) to 150.59, marking an increase of 5.85.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 27.00. This value is within the healthy range. It has increased from 21.86 (Mar 24) to 27.00, marking an increase of 5.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 16.11, marking an increase of 3.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 10.02, marking an increase of 2.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
- For PBDIT Margin (%), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 15.10 (Mar 24) to 17.92, marking an increase of 2.82.
- For PBIT Margin (%), as of Mar 25, the value is 10.70. This value is within the healthy range. It has increased from 8.51 (Mar 24) to 10.70, marking an increase of 2.19.
- For PBT Margin (%), as of Mar 25, the value is 6.65. This value is below the healthy minimum of 10. It has increased from 5.35 (Mar 24) to 6.65, marking an increase of 1.30.
- For Net Profit Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 5. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 8. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.19. This value is below the healthy minimum of 15. It has increased from 5.86 (Mar 24) to 7.19, marking an increase of 1.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.44. This value is within the healthy range. It has increased from 8.77 (Mar 24) to 11.44, marking an increase of 2.67.
- For Return On Assets (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 5. It has increased from 2.79 (Mar 24) to 3.59, marking an increase of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.29, marking a decrease of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.68 (Mar 24) to 0.60, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.74. It has increased from 0.73 (Mar 24) to 0.74, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has decreased from 1.28 (Mar 24) to 1.26, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.87 (Mar 24) to 0.83, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 5.83, marking an increase of 3.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 21.25 (Mar 24) to 0.00, marking a decrease of 21.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.90 (Mar 24) to 0.00, marking a decrease of 7.90.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 78.75 (Mar 24) to 0.00, marking a decrease of 78.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.10 (Mar 24) to 0.00, marking a decrease of 92.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.43, marking a decrease of 0.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 3. It has decreased from 2.23 (Mar 24) to 2.21, marking a decrease of 0.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,685.34. It has increased from 4,058.84 (Mar 24) to 5,685.34, marking an increase of 1,626.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.06. This value exceeds the healthy maximum of 3. It has increased from 2.27 (Mar 24) to 3.06, marking an increase of 0.79.
- For EV / EBITDA (X), as of Mar 25, the value is 17.05. This value exceeds the healthy maximum of 15. It has increased from 15.06 (Mar 24) to 17.05, marking an increase of 1.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 78.74 (Mar 24) to 0.00, marking a decrease of 78.74.
- For Price / BV (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 2.75 (Mar 24) to 3.91, marking an increase of 1.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hikal Ltd:
- Net Profit Margin: 4.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.44% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 286 (Industry average Stock P/E: 52.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 717/718, Maker Chambers V, Mumbai Maharashtra 400021 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jai Hiremath | Executive Chairman |
| Mr. Sameer Hiremath | Vice Chairman & Mng.Director |
| Mr. Sarangan Suresh | Whole Time Director |
| Ms. Sugandha Hiremath | Non Executive Director |
| Mr. Amit Kalyani | Non Executive Director |
| Mrs. Shivani Bhasin Sachdeva | Ind. Non-Executive Director |
| Mr. Shrikrishna Adivarekar | Ind. Non-Executive Director |
| Mr. Ramachandra Kaundinya | Ind. Non-Executive Director |
| Mr. Berjis Desai | Ind. Non-Executive Director |
| Mr. Ravi Kapoor | Ind. Non-Executive Director |
| Mr. Ranjana S Salgaocar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Hikal Ltd?
Hikal Ltd's intrinsic value (as of 29 December 2025) is 1646.02 which is 603.43% higher the current market price of 234.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 2,885 Cr. market cap, FY2025-2026 high/low of 457/217, reserves of ₹1,170 Cr, and liabilities of 2,349 Cr.
What is the Market Cap of Hikal Ltd?
The Market Cap of Hikal Ltd is 2,885 Cr..
What is the current Stock Price of Hikal Ltd as on 29 December 2025?
The current stock price of Hikal Ltd as on 29 December 2025 is 234.
What is the High / Low of Hikal Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hikal Ltd stocks is 457/217.
What is the Stock P/E of Hikal Ltd?
The Stock P/E of Hikal Ltd is 286.
What is the Book Value of Hikal Ltd?
The Book Value of Hikal Ltd is 96.9.
What is the Dividend Yield of Hikal Ltd?
The Dividend Yield of Hikal Ltd is 0.60 %.
What is the ROCE of Hikal Ltd?
The ROCE of Hikal Ltd is 9.85 %.
What is the ROE of Hikal Ltd?
The ROE of Hikal Ltd is 7.38 %.
What is the Face Value of Hikal Ltd?
The Face Value of Hikal Ltd is 2.00.